About this trial
The aim of this study is to evaluate the associations of self-compassion and self-efficacy levels with symptom severity, functional status, and quality of life in individuals with Parkinson's disease.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Clinically diagnosed Parkinson's disease
Disqualifiers
Presence of psychiatric disorders (e.g., major depression, psychotic disorders)
Trial population
The study population will consist of individuals diagnosed with Parkinson's disease who are classified as Hoehn and Yahr stage 1-3, aged between 40 and 85 years, and have sufficient cognitive function (MMSE ≥ 24). Participants will be recruited from patients attending the Movement Disorders Outpatient Clinic of the Neurology Department
Trial design
Cohort
Cross-sectional
Treatments tested in this trial
Self-Report Questionnaire Assessment
Other interventionThis study does not involve any therapeutic intervention. Participants will complete a set of self-report questionnaires assessing self-compassion, self-efficacy, symptom severity, functional status, and quality of life. Data will be collected in a single session for observational analysis.
Treatment groups
Trial outcomes
Primary outcomes
Self-Compassion Scale (SCS) Total Score
Self-compassion will be measured using the Self-Compassion Scale (SCS), a validated self-report instrument assessing multiple dimensions of self-compassion. The total score will be calculated, with higher scores indicating greater self-compassion.
Self-Efficacy for Managing Chronic Disease 6-Item Scale Total Score
Self-efficacy will be measured using the Self-Efficacy for Managing Chronic Disease 6-Item Scale, a validated self-report measure. The total score will be calculated, with higher scores indicating greater perceived self-efficacy.
Unified Parkinson's Disease Rating Scale (UPDRS) Total Score
Symptom severity will be measured using the Unified Parkinson's Disease Rating Scale (UPDRS), a validated clinician-rated instrument assessing motor and non-motor symptoms. Higher total scores indicate greater disease severity.
Secondary outcomes
Timed Up and Go (TUG) Test Completion Time in Seconds
Functional mobility will be measured using the Timed Up and Go (TUG) test. The time required to stand up from a chair, walk 3 meters, turn, return, and sit down will be recorded in seconds. Longer times indicate poorer functional mobility.
Six-Minute Walk Test (6MWT) Distance in Meters
Functional exercise capacity will be measured using the Six-Minute Walk Test (6MWT). The total distance walked in six minutes will be recorded in meters. Greater distances indicate better functional capacity.
Mini-Balance Evaluation Systems Test (Mini-BESTest) Total Score
Dynamic balance will be measured using the Mini-Balance Evaluation Systems Test (Mini-BESTest), a 14-item performance-based assessment. Total scores range from 0 to 28, with higher scores indicating better balance performance.
Parkinson's Disease Questionnaire-39 (PDQ-39) Total Score
Quality of life will be measured using the Parkinson's Disease Questionnaire-39 (PDQ-39), a validated disease-specific instrument. Total scores range from 0 to 100, with higher scores indicating poorer quality of life.
Locations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: